LNTH — Lantheus Holdings Share Price
- $6.21bn
- $5.91bn
- $1.30bn
- 98
- 55
- 61
- 82
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 13.21 | ||
PEG Ratio (f) | 6.58 | ||
EPS Growth (f) | 2.05% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 5.26 | ||
Price to Tang. Book | 6.57 | ||
Price to Free Cashflow | 16.39 | ||
Price to Sales | 4.15 | ||
EV to EBITDA | 10.88 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 37.98% | ||
Return on Equity | 45.53% | ||
Operating Margin | 32.11% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 347.34 | 339.41 | 425.21 | 935.06 | 1,296.43 | 1,519.59 | 1,579.36 | 30.44% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -17.99 | -95.04 | n/a | n/a | +1324.35 | +16.9 | +0.91 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.
Directors
- Brian Markison NEC (56)
- Mary Heino PRE (61)
- Robert Marshall CFO (54)
- Vivian Yao CHO
- Daniel Niedzwiecki SVP
- Etienne Montagut SVP (46)
- Carol Walker SVP (58)
- Linda Lennox VPR (56)
- Paul Blanchfield OTH (40)
- Gerard Ber IND (63)
- Samuel Leno IND (75)
- Heinz Maeusli IND (58)
- Julie Mchugh IND (56)
- Gary Pruden IND (60)
- James Thrall IND (77)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- November 30th, 2007
- Public Since
- June 25th, 2015
- No. of Shareholders
- 30
- No. of Employees
- 834
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 69,526,841
- Address
- 331 Treble Cove Rd, NORTH BILLERICA, 01862
- Web
- https://www.lantheus.com/
- Phone
- +1 9786718001
- Contact
- Mark Kinarney
- Auditors
- Deloitte & Touche LLP
Upcoming Events for LNTH
Lantheus Holdings Inc Annual Shareholders Meeting
Q1 2025 Lantheus Holdings Inc Earnings Release
Similar to LNTH
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
As of Today at 20:44 UTC, shares in Lantheus Holdings are trading at $89.27. This share price information is delayed by 15 minutes.
Shares in Lantheus Holdings last closed at $89.27 and the price had moved by +24.64% over the past 365 days. In terms of relative price strength the Lantheus Holdings share price has underperformed the S&P500 Index by -4.53% over the past year.
The overall consensus recommendation for Lantheus Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLantheus Holdings does not currently pay a dividend.
Lantheus Holdings does not currently pay a dividend.
Lantheus Holdings does not currently pay a dividend.
To buy shares in Lantheus Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $89.27, shares in Lantheus Holdings had a market capitalisation of $6.21bn.
Here are the trading details for Lantheus Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LNTH
Based on an overall assessment of its quality, value and momentum Lantheus Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lantheus Holdings is $134.00. That is 50.11% above the last closing price of $89.27.
Analysts covering Lantheus Holdings currently have a consensus Earnings Per Share (EPS) forecast of $6.70 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lantheus Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -3.92%.
As of the last closing price of $89.27, shares in Lantheus Holdings were trading +2.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lantheus Holdings PE ratio based on its reported earnings over the past 12 months is 13.21. The shares last closed at $89.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lantheus Holdings' management team is headed by:
- Brian Markison - NEC
- Mary Heino - PRE
- Robert Marshall - CFO
- Vivian Yao - CHO
- Daniel Niedzwiecki - SVP
- Etienne Montagut - SVP
- Carol Walker - SVP
- Linda Lennox - VPR
- Paul Blanchfield - OTH
- Gerard Ber - IND
- Samuel Leno - IND
- Heinz Maeusli - IND
- Julie Mchugh - IND
- Gary Pruden - IND
- James Thrall - IND